Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta‐Analysis Approach-Reference-Cited by-同舟云学术

Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta‐Analysis Approach

Published:2021-11-08 Issue:2 Volume:111 Page:509-518
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin Pharma and Therapeutics

Author:

Lingineni Karthik¹,Chaturvedula Ayyappa²,Cicali Brian¹,Cristofoletti Rodrigo¹,Wendl Thomas³,Hoechel Joachim³,Brown Joshua D.⁴,Vozmediano Valvanera¹,Schmidt Stephan¹

Affiliation:

1. Department of Pharmaceutics Center for Pharmacometrics and Systems Pharmacology College of Pharmacy University of Florida Orlando Florida USA

2. The University of North Texas Health Science Center Fort Worth Texas USA

3. Bayer AG Leverkusen Germany

4. Department of Pharmaceutical Outcomes & Policy Center for Drug Evaluation & Safety College of Pharmacy University of Florida Gainesville Florida USA

Funder

Bill and Melinda Gates Foundation

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2457

Reference26 articles.

1. Nations U.Department of Economic and Social Affairs Population Division (2019). Contraceptive Use by Method 2019: Data Booklet (ST/ESA/SER.A/435).

2. FDA Public Meeting Report on “Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications”

3. Establishing a Multidisciplinary Framework to Study Drug-Drug Interactions of Hormonal Contraceptives: An Invitation to Collaborate

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically based pharmacokinetic modeling in obesity: applications and challenges;Expert Opinion on Drug Metabolism & Toxicology;2024-08-12

2. Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings;PLOS ONE;2024-06-05

3. Model-Based Analysis of In Vivo Release Data of Levonorgestrel Implants: Projecting Long-Term Systemic Exposure;Pharmaceutics;2023-05-02

4. Development and validation of a multiplexed assay for the measurement of long-acting hormonal contraceptives in plasma via liquid chromatography-tandem mass spectrometry;Journal of Pharmaceutical and Biomedical Analysis;2023-05

5. Development of a Translational Exposure‐Bracketing Approach to Streamline the Development of Hormonal Contraceptive Drug Products;Clinical Pharmacology & Therapeutics;2022-07-18